Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2011 Jul 26;6(7):e22797. doi: 10.1371/journal.pone.0022797

Progressive Reduction of its Expression in Rods Reveals Two Pools of Arrestin-1 in the Outer Segment with Different Roles in Photoresponse Recovery

Whitney M Cleghorn 1, Elviche L Tsakem 1, Xiufeng Song 1, Sergey A Vishnivetskiy 1, Jungwon Seo 1,¤, Jeannie Chen 2, Eugenia V Gurevich 1, Vsevolod V Gurevich 1,*
Editor: Rafael Linden3
PMCID: PMC3144249  PMID: 21818392

Abstract

Light-induced rhodopsin signaling is turned off with sub-second kinetics by rhodopsin phosphorylation followed by arrestin-1 binding. To test the availability of the arrestin-1 pool in dark-adapted outer segment (OS) for rhodopsin shutoff, we measured photoresponse recovery rates of mice with arrestin-1 content in the OS of 2.5%, 5%, 60%, and 100% of wild type (WT) level by two-flash ERG with the first (desensitizing) flash at 160, 400, 1000, and 2500 photons/rod. The time of half recovery (thalf) in WT retinas increases with the intensity of the initial flash, becoming ∼2.5-fold longer upon activation of 2500 than after 160 rhodopsins/rod. Mice with 60% and even 5% of WT arrestin-1 level recovered at WT rates. In contrast, the mice with 2.5% of WT arrestin-1 had a dramatically slower recovery than the other three lines, with the thalf increasing ∼28 fold between 160 and 2500 rhodopsins/rod. Even after the dimmest flash, the rate of recovery of rods with 2.5% of normal arrestin-1 was two times slower than in other lines, indicating that arrestin-1 level in the OS between 100% and 5% of WT is sufficient for rapid recovery, whereas with lower arrestin-1 the rate of recovery dramatically decreases with increased light intensity. Thus, the OS has two distinct pools of arrestin-1: cytoplasmic and a separate pool comprising ∼2.5% that is not immediately available for rhodopsin quenching. The observed delay suggests that this pool is localized at the periphery, so that its diffusion across the OS rate-limits the recovery. The line with very low arrestin-1 expression is the first where rhodopsin inactivation was made rate-limiting by arrestin manipulation.

Introduction

Humans express ∼800 different G-protein-coupled receptors (GPCR), among which rhodopsin is the best characterized [1]. The biochemical mechanism of rod phototransduction serves as a model of GPCR-driven signaling cascades [1]. Rhodopsin is activated by photoconversion of covalently attached retinal. Light-activated rhodopsin catalyzes nucleotide exchange of cognate G protein transducin, which then activates cGMP phosphodiesterase. Rhodopsin is inactivated by GRK1 phosphorylation, followed by high-affinity binding of arrestin-1 when three attached phosphates are accumulated [2], [3]. Comprehensive understanding of systems behavior of rod photoreceptors requires the knowledge of exact concentration, localization, and activity of every signaling protein in the cell. While the functional role of many players in rod phototransduction have been qualitatively established using genetically modified mice (reviewed in [4]), the biological significance of the exact expression level of each protein was rarely addressed experimentally. The studies where rods with different expression levels of rhodopsin [5], [6], RGS9 [7], [8], GRK1 [9], and arrestin [8][10] were functionally characterized yielded important, often surprising, results. Mouse rods express arrestin-1 and rhodopsin at ∼0.8∶1 ratio, which makes arrestin-1 the second most abundant protein in the rod photoreceptor [10][12]. Using transgenic mice expressing arrestin-1 at levels ranging from 4 to 220% of WT, we recently found that supra-physiological arrestin-1 levels marginally improve the functional performance of rods [10]. In addition, rod photoreceptors with arrestin-1 levels below WT perform as well as other genotypes at dim light, but show dramatic functional impairment when tested at brighter illumination. [10]. Importantly, the reduction of arrestin-1 level in the OS to ∼2.5% of WT dramatically slowed the recovery kinetics, as compared to mice with only twice as much arrestin-1 in the OS [10]. Here we show that, while the recovery rates in all lines slow with the increased intensity of the desensitizing flash, the same “threshold” between 5% and 2.5% of arrestin-1 level in the OS is observed at all flash intensities tested. Remarkably, this threshold is maintained even at the dimmest desensitizing flash. These data indicate that ∼2.5% of arrestin-1 content in the OS is not immediately available for rhodopsin quenching, suggesting that this separate pool of arrestin-1 resides relatively far from rhodopsin-containing discs. Slow diffusion of arrestin-1 across the OS in the lowest expressing line apparently delays the recovery by making rhodopsin inactivation rate-limiting, in contrast to WT and arrestin-1 hemizygous (Arr1+/−) animals where transducin inactivation is the slowest process that determines the speed of recovery [7], [8], [13]. Please note that we use systematic names of arrestin proteins: arrestin-1 (historic names S-antigen, 48 kDa protein, visual or rod arrestin), arrestin-2 (β-arrestin or β-arrestin1), arrestin-3 (β-arrestin2 or hTHY-ARRX), and arrestin-4 (cone or X-arrestin; for unclear reasons its gene is called “arrestin 3” in HUGO database).

Results

Arrestin-1 binding after GRK1 phosphorylation of rhodopsin [14], [15] is the key process in rapid photoresponse recovery in rods [16] and cones [17]. Arrestin-1 acts by sterically shielding rhodopsin, precluding further transducsin activation [18], [19]. In the dark, arrestin1 translocates out of OS and localizes primarily to cell bodies of rod photoreceptors, so the OS contains only a small proportion of arrestin-1 [10][12], [20][22]. Dark-adapted rod OS of transgenic mice expressing arrestin-1 at 4% (Tr-4Arr−/−), 12% (Tr-12Arr−/−), 50% (Arr+/−), and 100% of WT contain ∼7.6, 15, 180, and 300 µM arrestin-1, respectively (these calculations are based on 3 mM rhodopsin concentration in the OS [10], [23]), which constitutes 2.5%, 5%, 60%, and 100% of normal WT level, respectively. Rod function can be monitored non-invasively by ERG, where the negative a-wave reflects the hyperpolarization of the rod cells caused by reduction of circulating current [24][27]. We used double-flash protocol, where an initial flash desensitizes rods, and the response to the second (probe) flash, delivered at varying time intervals after the initial flash, is measured to determine the extent of recovery. The time of half-recovery (thalf) is calculated by plotting the amplitude of the probe flash response as a function of time between flashes [24], [28]. Using desensitizing flash of −0.4 logcd*s/m2 (400 photoisomerizations/rod), we previously found that recovery rates of the three lines with 100%, 60%, and 5% of WT arrestin-1 level in the OS are surprisingly similar, whereas rod recovery in mice with 2.5% of normal arrestin-1 content in the OS is dramatically slowed (Fig. 1) [10]. Considering that the pseudo-first-order rate of arrestin-1 binding to phosphorylated rhodopsin is the product of the on-rate constant (which was recently measured [29]) multiplied by the absolute arrestin-1 concentration near rhodopsin-containing discs, two mechanistic models could account for this “threshold”-like effect. If arrestin-1 is homogeneously distributed throughout OS cytoplasm, the threshold must depend on the intensity of the desensitizing flash, so that the activation of more than twice as many rhodopsins should place Tr-12Arr−/− mice with two-fold greater arrestin-1 content below the threshold. Alternatively, arrestin-1 distribution in the OS may be non-homogeneous, with immediately available and relatively unavailable pools. If the latter pool is roughly equal to arrestin-1 content in the lowest expressing animals, Tr-4Arr−/− mice would be below the threshold at all intensities of desensitizing flash, whereas all other lines would remain above it. To distinguish between these two possibilities, we used initial desensitizing flashes with intensities that vary ∼16-fold, −0.8, −0.4, 0, and +0.4 logcd*s/m2, corresponding to 160, 400, 1000, and 2500 photoisomerizations/rod (Figs. 1,2; Table 1) [30]. Unexpectedly, we found no significant differences in the thalf of WT, Arr+/−, and Tr-12Arr−/− mice at any intensity of desensitizing flash tested, despite ∼20-fold difference in the arrestin-1 content in the OS of WT and Tr-12Arr−/− animals. However, the magnitude of the recovery defect in Tr-4Arr−/− mice depended on flash intensity. At 160 photoisomerizations/rod, thalf of Tr-4Arr−/− mice was only ∼1.8-fold longer than in other genotypes, but the difference increased to ∼5.5-, 12-, and 23-fold at 400, 1000, and 2500 photoisomerizations/rod, respectively (Fig. 2; Table 1).

Figure 1. Reduced arrestin-1 expression slows down photoresponse recovery.

Figure 1

The intensities of the first (desensitizing) flashes were −0.8, −0.4, 0, or +0.4 logcd*s/m2 and second (probe) flash was 0.65 logcd*s/m2. The a-wave elicited by the probe flash was plotted as a function of time elapsed after the first flash. Representative recovery curves for indicated genotypes and strengths of desensitizing flash are shown. The interval between the two flashes was varied from 200 to 120,000 ms. The results for desensitizing flash of −0.4 logcd*s/m2 were reported previously [10], and are shown here for comparison. Phi/rod, photoisomerizations/rod. [59]

Figure 2. Animals with very low arrestin-1 in the OS show very long time of half recovery.

Figure 2

To calculate the time of half recovery, recovery kinetics were fitted by polynomial nonlinear regression, with R2>0.95, as described in methods. Means +/− SD for four animals per genotype are shown. The data were analyzed by one-way ANOVA with Genotype as main factor followed by Bonferroni post hoc comparison of means. * - p<0.05; ** - p<.001, *** - p<0.001 to WT; + - p<0.05, ++ - p<0.001, +++ - p<0.001 to Arr+/−, a – p<0.005, b – p<0.01, c – p<0.001 to Tr-12Arr−/−. Phi/rod, photoisomerizations/rod.

Table 1. The rates of photoresponse recovery in mice with different arrestin-1 expression.

Genotype 158 phi/rod 398 phi/rod 1000 phi/rod 2512 phi/rod Arrestin-1 concentration (OS)
Wild type 258±45 ms 376±47 ms 405±58 ms 646±56 ms 300 µM
Arr1+/− 262±35 ms 426±26 ms 486±82 ms 626±79 ms 180 µM
Tr-12Arr1−/− 278±46 ms 433±45 ms 460±75 ms 718±27 ms 15 µM
Tr-4 Arr1−/− 514±183 ms 2368±1515 ms 5515±999 ms 14137±3595 ms 7.6 µM

Importantly, WT, Arr+/−, and Tr-12Arr−/− mice demonstrated a gradual slowing of the recovery with increasing intensity of the desensitizing flash, and the slope of the slowing was the same in these three genotypes, as evidenced by lack of interaction between Genotype and Light factors in two-way-ANOVA (F(6,41)-1.12, p = 0.37 n.s.). In these genotypes thalf increased ∼2.5-fold with desensitizing flash inducing 2,500 instead of 160 photoisomerizations/rod (Table 1). In sharp contrast, the increase in recovery time from the dimmest to brightest desensitizing flash for Tr-4Arr−/− mice was ∼28 fold (Table 1). Virtually identical slowing of the recovery in WT, Arr+/−, and Tr-12Arr−/− animals likely reflects the increased time that it takes guanylyl cyclase to replenish hydrolyzed cGMP necessary to open cGMP-gated channels and restore circulating current, whereas much more dramatic increase of thalf in Tr-4Arr−/− animals must reflect additional processes that do not operate in the other three genotypes.

Discussion

Rod phototransduction is the only GPCR-driven signaling cascade where the expression levels of all players are known with sufficient accuracy to model systems behavior of the cell [13], [31][33] Here we report an unexpected finding that 20-fold reduction of arrestin-1 content in the dark-adapted rod OS from 100% to 5% of WT level has no appreciable effect on photoresponse recovery, whereas further 2-fold reduction to 2.5% dramatically slows this process (Figs. 1,2; Table 1). This remarkable difference in recovery kinetics is unlikely to be simply the result of depletion of arrestin-1 in the OS. There are ∼70 million rhodopsin molecules in the mouse OS [30], clustered on approximately 800 discs. This corresponds to ∼88,000 rhodopsins per disc. The calculated amount of arrestin-1 present in the OS for Tr-4Arr−/− mice is approximately 7.6 µM, which corresponds to about 200,000 molecules per OS [10]. In the case of even arrestin-1 distribution in the OS, there would be ∼250 arrestin-1 molecules per disc available to quench rhodopsin. However, even at the dimmest desensitizing flash used, which generates only 160 Rh*/rod (0.2 Rh*/disc), we observed a 1.8-fold slowing of the recovery, which increases to >20-fold at ∼3 Rh*/disc (Table 1). Arrestin-1 concentration in the WT mouse OS is ∼300 µM [10]. Taking into account known constants of mouse arrestin-1 self-association [34], this yields ∼50 µM active monomer. This results in estimated pseudo-first-order on-rate of 50 s−1, enabling arrestin-1 to “check” the state of each rhodopsin molecule every 20 msec. This is consistent with recent estimates of an active rhodopsin lifetime of <60 ms [7], or possibly even ∼30 ms [8], [13]. Calculations show that despite the dramatically reduced arrestin-1 concentration in Tr-4Arr−/− mice, at 7.6 µM there is still enough arrestin-1 monomers in the OS to encounter each rhodopsin every 200 ms. This difference is sufficient to account for ∼200 ms delay, but cannot explain the multi-second times of half-recovery observed (Fig. 2; Table 1). Thus, our data suggest that most of arrestin-1 in the OS of Tr-4Arr−/− animals is not immediately available for rhodopsin quenching.

Self-association could potentially limit arrestin-1 availability. Arrestin-1 forms dimers and tetramers at physiological concentrations [35][37], yet only the monomer is capable of binding rhodopsin [37], [38], because the well-defined rhodopsin-binding surface of each molecule [39][47] is occluded by other subunits in the solution tetramer and both possible dimers [38]. Recent measurements of self-association constants of mouse arrestin-1 yielded Kd dimer  = 57.5 µM and Kd tetramer  = 63.1 µM [34]. These values allow the calculation of the half-life of the dimer and tetramer [48], both of which turn out to be on the order of 12 ms. Thus, arrestin-1 self-association also cannot account for the multi-second times of half-recovery in Tr-4Arr−/− mice (Table 1).

Sub-cellular distribution of arrestin-1 in rods is strictly light dependent. In the dark, arrestin-1 is predominantly located in the inner segment, perinuclear layer, and synaptic terminals, with relatively small fraction, estimated at 2–4% [12], [49], 9% [11], or ∼15% [10], residing in the OS. Prolonged bright illumination triggers the translocation of the majority of arrestin-1 to the OS [20], [49], [50]. Different lines of evidence suggest that arrestin-1 movement is either energy-independent, driven by diffusion [49], may involve active transport [51], or possibly diffusion with active gating in the cilium [11]. Considering that in the light and dark arrestin-1 in the rod is at disequilibrium [52], it is clear that, regardless of the mode of transportation, its distribution must be determined by the interactions with non-mobile partners: otherwise the diffusion would quickly ruin concentration gradients created by any mechanism [53]. Arrestin-1 binds rhodopsin at 1∶1 ratio [54], [55], and the molar amount of arrestin-1 that can translocate to the OS in the light is limited by the amount of rhodopsin present in this compartment [12], indicating that rhodopsin is the immobile binding partner that holds arrestin-1 in the OS in the light. Arrestin-1 binds several proteins present in the cell body, including polymerized tubulin (microtubules) [56], [57], c-Jun N-terminal kinase [58], ubiquitin ligases Mdm2 [58] and parkin [59], calmodulin [60], N-ethylmaleimide-sensitive factor [61], and enolase1 [62]. Among these, however, tubulin appears to be the only sufficiently abundant protein to serve as an “anchor” for arrestin-1 expressed at 0.8∶1 ratio to rhodopsin [10]-[12]. High concentration of arrestin-1 in the compartments particularly rich in microtubules (the inner segment, perinuclear area, and synaptic terminals [63]) in the dark supports this notion. Arrestin-1 translocation is a relatively slow process that takes many minutes [11], [49], [50]. Thus, in dark-adapted animals used in this study arrestin-1 already present in the OS must be responsible for signal shutoff. Microtubules are not abundant in the OS, but several bundles near the outer membrane extend along the full length of the OS and the axoneme [21], [63]. Interestingly, arrestin-1 association with microtubules in the OS was previously reported [64], [65]. The diameter of mouse rod OS is ∼1.4 µm [31], so that arrestin-1 bound to these microtubules would need to diffuse for up to 0.7 µm before reaching rhodopsin. This would take seconds [31], which matches the observed delay of photoresponse recovery in Tr-4Arr−/− mice, as compared to the Tr-12Arr−/− animals (Table 1), fairly well. Importantly, the observed delay of several seconds (Table 1) cannot be explained by arrestin-1 diffusion into the OS from the inner segment: the time arrestin-1 would require to diffuse over the ∼23 µm length of the rod OS would be significantly longer. Even if one takes into account that in Tr-12Arr−/− and Tr-4Arr−/− mice the OS are shorter (∼17 µm and 14 µm in the middle retina, respectively [10]), arrestin-1 diffusion across this distance would take minutes before it can quench rhodopsin in the OS. Although the exact amount of polymerized tubulin in the OS is unknown, if it is present in excess over arrestin-1 at any concentration that significantly exceeds KD of arrestin-1 binding [66], the majority of arrestin-1 would be recruited to microtubules. Thus, the simplest model that accounts for our data is that there are two distinct pools of arrestin-1 in the OS. At least 2.5% is bound to the microtubules at the plasma membrane, whereas the rest is distributed throughout OS cytoplasm, with only the latter being available to quench rhodopsin signaling on the millisecond timescale. In Tr-4Arr−/− animals microtubules take up most of the arrestin-1 present, leaving relatively little immediately available to rhodopsin. This slows down shutoff by the time necessary for arrestin-1 diffusion across the OS. In contrast, in Tr-12Arr−/− mice and higher expressors the microtubules in the OS apparently saturate by the amount of arrestin-1 roughly equal to that present in Tr-4Arr−/− animals, allowing the rest of arrestin-1 to freely distribute in the cytoplasm to be immediately available for rhodopsin shutoff.

In summary, our data suggest the existence of two distinct pools of arrestin-1 in dark-adapted mouse outer segments. To the best of our knowledge, so far only one genetically modified mouse line where rhodopsin shutoff was made rate-limiting was described: mice with low expression of GRK1/2 chimera [67]. In Tr-4Arr−/− mice we made rhodopsin shutoff the rate-limiting stage of photoresponse recovery by low expression of arrestin-1. Collectively, these results strongly support the idea that both phosphorylation and arrestin binding are necessary steps in rhodopsin shutoff.

Materials and Methods

Ethics Statement

Animal research was conducted in compliance with the NIH Guide for the Care and Use of Laboratory Animals and approved by the Vanderbilt University Institutional Animal Care and Use Committee/Office of Animal Welfare Assurance (protocol ID M/06/091).

Generation of transgenic mice expressing arrestin-1 at different levels

The generation of transgenic animals expressing arrestin-1 at various levels under the pRho4-1 rhodopsin promoter has been described previously [10], [12], [49], and the arrestin-1 content in the dark-adapted OS of these mice was quantified by Western blot [10].

Electroretinography (ERG)

Electroretinograms were recorded from 6 to 8 week old mice reared in 12/12 light-dark cycle (90±10 lux in the cage during light period). Animals were dark-adapted overnight, as described [10], [68]. Mice were anesthetized under dim red light by ip injection of (in µg/g body weight) 15–20 ketamine, 6–8 xylazine, 600–800 urethane in PBS. The pupils were dilated with 1% tropicamide in PBS before and throughout the experiment. An eye electrode made with a coiled 0.2 mm platinum wire was placed on the cornea, a tungsten needle reference electrode was placed in the cheek, and ground needle electrode in the tail [24], [30], [69]. ERG data was collected using the electrophysiologic system UTAS E-3000 (LKC Technologies, Inc.) connected to a Ganzfeld chamber that produced brief (from 20 µs to 1 ms) full field flash stimuli. The various light intensities used were calibrated by the manufacturer and computer controlled. Because mice are sensitive to temperature, animals were placed on a heating pad connected to a temperature control unit to maintain the temperature at 37–38°C throughout the experiment to reduce variability.

The double flash recording was used to analyze the kinetics of recovery [24], [25], [28], [70], [71]. A test flash was delivered to suppress the circulating current of the rod photoreceptors. The recovery was monitored by delivering a second (probe) flash after various time intervals between the two flashes, that ranged from 200 to 120,000 ms. The intensity of the test flash was either −0.8, −0.4, 0, or +0.4 logcd*s/m2, corresponding to ∼160, ∼400, ∼1000, and ∼2500 photoisomerizations per rod [30]. The following probe flash was 0.65 logcd*s/m2, corresponding to ∼4,500 isomerizations per rod [30]. Sufficient time for dark adaptation was allowed between trials, as determined by the reproducibility of the response to the test flash. Time-to-peak (implicit time) of the a-wave at the intensity of the probe flash was not significantly different in all four genotypes. This finding along with the shape of the a-wave indicates that the intrusion of b-wave and oscillation potentials [25], [28] did not differentially affect different genotypes. The normalized amplitude of the probe flash a-wave was plotted as a function of time between the two flashes. Instead of fitting the data points to a theoretical equation, which is inevitably based on certain assumptions that may not be correct for all of the genotypes used, we fitted curves with polynomial nonlinear regression using GraphPad Prism (Version 4.0) and considered R2>0.95 as a criterion for a good fit. The rate of recovery was characterized by the time interval necessary for half recovery (thalf), as described [10], [24], [28], [68].

Statistical Analysis

The data were analyzed by for each light level separately by one-way ANOVA with Genotype as main factor. To examine the change in recovery time with light intensity, the data for each genotype were analyzed separately with Light as main factor. Means were compared using Bonferroni post hoc test with correction for multiple comparisons. In all cases, p<0.05 was considered significant.

Footnotes

Competing Interests: The authors have declared that no competing interests exist.

Funding: Supported by National Institutes of Health grants T32 EY07135 (WMC), EY011500, GM077561, and GM081756 (VVG), NS045117 and NS065868 (EVG), EY012155 (JC), and P30 core grant in vision research EY008126 (to Vanderbilt University). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Luo DG, Xue T, Yau KW. How vision begins: an odyssey. Proc Natl Acad Sci U S A. 2008;105:9855–9862. doi: 10.1073/pnas.0708405105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Vishnivetskiy SA, Raman D, Wei J, Kennedy MJ, Hurley JB, et al. Regulation of arrestin binding by rhodopsin phosphorylation level. J Biol Chem. 2007;282:32075–32083. doi: 10.1074/jbc.M706057200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Mendez A, Burns ME, Roca A, Lem J, Wu LW, et al. Rapid and reproducible deactivation of rhodopsin requires multiple phosphorylation sites. Neuron. 2000;28:153–164. doi: 10.1016/s0896-6273(00)00093-3. [DOI] [PubMed] [Google Scholar]
  • 4.Makino CL, Wen XH, Lem J. Piecing together the timetable for visual transduction with transgenic animals. Curr Opin Neurobiol. 2003;13:404–412. doi: 10.1016/s0959-4388(03)00091-6. [DOI] [PubMed] [Google Scholar]
  • 5.Calvert PD, Govardovskii VI, Krasnoperova N, Anderson RE, Lem J, et al. Membrane protein diffusion sets the speed of rod phototransduction. Nature. 2001;411:90–94. doi: 10.1038/35075083. [DOI] [PubMed] [Google Scholar]
  • 6.Wen XH, Shen L, Brush RS, Michaud N, Al-Ubaidi MR, et al. Overexpression of rhodopsin alters the structure and photoresponse of rod photoreceptors. Biophys J. 2009;96:939–950. doi: 10.1016/j.bpj.2008.10.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Krispel CM, Chen D, Melling N, Chen YJ, Martemyanov KA, et al. RGS expression rate-limits recovery of rod photoresponses. Neuron. 2006;51:409–416. doi: 10.1016/j.neuron.2006.07.010. [DOI] [PubMed] [Google Scholar]
  • 8.Gross OP, Burns ME. Control of rhodopsin's active lifetime by arrestin-1 expression in mammalian cells. J Neurosci. 2010;30:3450–3457. doi: 10.1523/JNEUROSCI.5391-09.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Doan T, Azevedo AW, Hurley JB, Rieke F. Arrestin competition influences the kinetics and variability of the single-photon responses of mammalian rod photoreceptors. J Neurosci. 2009;29:11867–11879. doi: 10.1523/JNEUROSCI.0819-09.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Song X, Vishnivetskiy SA, Seo J, Chen J, Gurevich EV, et al. Arrestin-1 expression level in rods: Balancing functional performance and photoreceptor health. Neuroscience. 2011;174:37–49. doi: 10.1016/j.neuroscience.2010.11.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Strissel KJ, Sokolov M, Trieu LH, Arshavsky VY. Arrestin translocation is induced at a critical threshold of visual signaling and is superstoichiometric to bleached rhodopsin. J Neurosci. 2006;26:1146–1153. doi: 10.1523/JNEUROSCI.4289-05.2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hanson SM, Gurevich EV, Vishnivetskiy SA, Ahmed MR, Song X, et al. Each rhodopsin molecule binds its own arrestin. Proc Natl Acad Sci. 2007;104:3125–3128. doi: 10.1073/pnas.0610886104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Burns ME, Pugh EN RGS9 concentration matters in rod phototransduction. Biophys J. 2009;97:1538–1547. doi: 10.1016/j.bpj.2009.06.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Chen CK, Burns ME, Spencer M, Niemi GA, Chen J, et al. Abnormal photoresponses and light-induced apoptosis in rods lacking rhodopsin kinase. Proc Nat Acad Sci USA. 1999;96:3718–3722. doi: 10.1073/pnas.96.7.3718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Chen J, Makino CL, Peachey NS, Baylor DA, Simon MI. Mechanisms of rhodopsin inactivation in vivo as revealed by a COOH-terminal truncation mutant. Science. 1995;267:374–377. doi: 10.1126/science.7824934. [DOI] [PubMed] [Google Scholar]
  • 16.Xu J, Dodd RL, Makino CL, Simon MI, Baylor DA, et al. Prolonged photoresponses in transgenic mouse rods lacking arrestin. Nature. 1997;389:505–509. doi: 10.1038/39068. [DOI] [PubMed] [Google Scholar]
  • 17.Nikonov SS, Brown BM, Davis JA, Zuniga FI, Bragin A, et al. Mouse cones require an arrestin for normal inactivation of phototransduction. Neuron. 2008;59:462–474. doi: 10.1016/j.neuron.2008.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wilden U. Duration and amplitude of the light-induced cGMP hydrolysis in vertebrate photoreceptors are regulated by multiple phosphorylation of rhodopsin and by arrestin binding. Biochemistry. 1995;34:1446–1454. doi: 10.1021/bi00004a040. [DOI] [PubMed] [Google Scholar]
  • 19.Krupnick JG, Gurevich VV, Benovic JL. Mechanism of quenching of phototransduction: binding competition between arrestin and transducin for phosphorhodopsin. J Biol Chem. 1997;272:18125–18131. doi: 10.1074/jbc.272.29.18125. [DOI] [PubMed] [Google Scholar]
  • 20.Broekhuyse RM, Tolhuizen EF, Janssen AP, Winkens HJ. Light induced shift and binding of S-antigen in retinal rods. Curr Eye Res. 1985;4:613–618. doi: 10.3109/02713688508999993. [DOI] [PubMed] [Google Scholar]
  • 21.McGinnis JF, Matsumoto B, Whelan JP, Cao W. Cytoskeleton participation in subcellular trafficking of signal transduction proteins in rod photoreceptor cells. J Neurosci Res. 2002;67:290–297. doi: 10.1002/jnr.10120. [DOI] [PubMed] [Google Scholar]
  • 22.Philp NJ, Chang W, Long K. Light-stimulated protein movement in rod photoreceptor cells of the rat retina. FEBS Lett. 1987;225:127–132. doi: 10.1016/0014-5793(87)81144-4. [DOI] [PubMed] [Google Scholar]
  • 23.Pugh EN, Lamb TD. Phototransduction in vertebrate rods and cones: molecular mechanisms of amplification, recovery and light adaptation. In: Stavenga DG, editor. Handbook of biological physics Molecular mechanisms in visual transduction. Amsterdam: Elsevier; 2000. pp. 183–255. [Google Scholar]
  • 24.Lyubarsky AL, Pugh EN Recovery phase of the murine rod photoresponse reconstructed from electroretinographic recordings. Journal of Neuroscience. 1996;16:563–571. doi: 10.1523/JNEUROSCI.16-02-00563.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hetling JR, Pepperberg DR. Sensitivity and kinetics of mouse rod flash responses determined in vivo from paired-flash electroretinograms. J Physiol. 1999;516:593–609. doi: 10.1111/j.1469-7793.1999.0593v.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Robson JG, Frishman LJ. Response linearity and kinetics of the cat retina: the bipolar cell component of the dark-adapted electroretinogram. Visual Neuroscience. 1995;12:837–850. doi: 10.1017/s0952523800009408. [DOI] [PubMed] [Google Scholar]
  • 27.Robson JG, Frishman LJ. Photoreceptor and bipolar cell contributions to the cat electroretinogram: a kinetic model for the early part of the flash response. Journal of the Optical Society of America, A, Optics, Image Science, & Vision. 1996;13:613–622. doi: 10.1364/josaa.13.000613. [DOI] [PubMed] [Google Scholar]
  • 28.Pepperberg DR, Birch DG, Hood DC. Photoresponses of human rods in vivo derived from paired-flash electroretinograms. Vis Neurosci. 1997;14:73–82. doi: 10.1017/s0952523800008774. [DOI] [PubMed] [Google Scholar]
  • 29.Bayburt TH, Vishnivetskiy SA, McLean M, Morizumi T, Huang CC, et al. Rhodopsin monomer is sufficient for normal rhodopsin kinase (GRK1) phosphorylation and arrestin-1 binding. J Biol Chem. 2011;286:1420–1428. doi: 10.1074/jbc.M110.151043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Lyubarsky AL, Daniele LL, Pugh EN From candelas to photoisomerizations in the mouse eye by rhodopsin bleaching in situ and the light-rearing dependence of the major components of the mouse ERG. Vision Res. 2004;44:3235–3251. doi: 10.1016/j.visres.2004.09.019. [DOI] [PubMed] [Google Scholar]
  • 31.Shen L, Caruso G, Bisegna P, Andreucci D, Gurevich VV, et al. Dynamics of mouse rod phototransduction and its sensitivity to variation of key parameters. IET Syst Biol. 2010;4:12–32. doi: 10.1049/iet-syb.2008.0154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Burns ME, Pugh EN Lessons from photoreceptors: turning off g-protein signaling in living cells. Physiology (Bethesda) 2010;25:72–84. doi: 10.1152/physiol.00001.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Caruso G, Bisena P, Lenoci L, Andreucci D, Gurevich VV, et al. Kinetics of rhodopsin inactivation and its role in regulating recovery and reproducibility of rod photoresponse. PLoS Computational Biology. 2010;6:e1001031. doi: 10.1371/journal.pcbi.1001031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Kim M, Hanson SM, Vishnivetskiy SA, Song X, Cleghorn WM, et al. Robust self-association is a common feature of mammalian visual arrestin-1. Biochemistry. 2011;50:2235–2242. doi: 10.1021/bi1018607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Schubert C, Hirsch JA, Gurevich VV, Engelman DM, Sigler PB, et al. Visual arrestin activity may be regulated by self-association. J Biol Chem. 1999;274:21186–21190. doi: 10.1074/jbc.274.30.21186. [DOI] [PubMed] [Google Scholar]
  • 36.Imamoto Y, Tamura C, Kamikubo H, Kataoka M. Concentration-dependent tetramerization of bovine visual arrestin. Biophys J. 2003;85:1186–1195. doi: 10.1016/S0006-3495(03)74554-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Hanson SM, Van Eps N, Francis DJ, Altenbach C, Vishnivetskiy SA, et al. Structure and function of the visual arrestin oligomer. EMBO J. 2007;26:1726–1736. doi: 10.1038/sj.emboj.7601614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hanson SM, Dawson ES, Francis DJ, Van Eps N, Klug CS, et al. A model for the solution structure of the rod arrestin tetramer. Structure. 2008;16:924–934. doi: 10.1016/j.str.2008.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kim M, Hanson SM, Vishnivetskiy SA, Song X, Cleghorn WM, et al. Robust self-association is a common feature of mammalian visual arrestin-1. Biochemistry. 2011;50 doi: 10.1021/bi1018607. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Gurevich VV, Benovic JL. Visual arrestin interaction with rhodopsin: Sequential multisite binding ensures strict selectivity towards light-activated phosphorylated rhodopsin. J Biol Chem. 1993;268:11628–11638. [PubMed] [Google Scholar]
  • 41.Gurevich VV, Benovic JL. Visual arrestin binding to rhodopsin: diverse functional roles of positively charged residues within the phosphorylation-recignition region of arrestin. J Biol Chem. 1995;270:6010–6016. doi: 10.1074/jbc.270.11.6010. [DOI] [PubMed] [Google Scholar]
  • 42.Gurevich VV, Dion SB, Onorato JJ, Ptasienski J, Kim CM, et al. Arrestin interaction with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, b2-adrenergic, and m2 muscarinic cholinergic receptors. J Biol Chem. 1995;270:720–731. doi: 10.1074/jbc.270.2.720. [DOI] [PubMed] [Google Scholar]
  • 43.Vishnivetskiy SA, Hosey MM, Benovic JL, Gurevich VV. Mapping the arrestin-receptor interface: structural elements responsible for receptor specificity of arrestin proteins. J Biol Chem. 2004;279:1262–1268. doi: 10.1074/jbc.M308834200. [DOI] [PubMed] [Google Scholar]
  • 44.Vishnivetskiy SA, Francis DJ, Van Eps N, Kim M, Hanson SM, et al. The role of arrestin alpha-helix I in receptor binding. J Mol Biol. 2010;395:42–54. doi: 10.1016/j.jmb.2009.10.058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Vishnivetskiy SA, Gimenez LE, Francis DJ, Hanson SM, Hubbell WL, et al. Few residues within an extensive binding interface drive receptor interaction and determine the specificity of arrestin proteins. J Biol Chem. 2011;286 doi: 10.1074/jbc.M110.213835. in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Hanson SM, Francis DJ, Vishnivetskiy SA, Kolobova EA, Hubbell WL, et al. Differential interaction of spin-labeled arrestin with inactive and active phosphorhodopsin. Proc Natl Acad Sci U S A. 2006;103:4900–4905. doi: 10.1073/pnas.0600733103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Hanson SM, Gurevich VV. The differential engagement of arrestin surface charges by the various functional forms of the receptor. J Biol Chem. 2006;281:3458–3462. doi: 10.1074/jbc.M512148200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Gurevich VV, Hanson SM, Gurevich EV, Vishnivetskiy SA. How rod arrestin achieved perfection: regulation of its availability and binding selectivity. In: Kisselev O, Fliesler SJ, editors. Methods in signal transduction series. Boca Raton, FL: CRC Press; 2007. pp. 55–88. [Google Scholar]
  • 49.Nair KS, Hanson SM, Mendez A, Gurevich EV, Kennedy MJ, et al. Light-dependent redistribution of arrestin in vertebrate rods is an energy-independent process governed by protein-protein interactions. Neuron. 2005;46:555–567. doi: 10.1016/j.neuron.2005.03.023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Elias RV, Sezate SS, Cao W, McGinnis JF. Temporal kinetics of the light/dark translocation and compartmentation of arrestin and alpha-transducin in mose photoreceptor cells. Mol Vis. 2004;10 [PubMed] [Google Scholar]
  • 51.Orisme W, Li J, Goldmann T, Bolch S, Wolfrum U, et al. Light-dependent translocation of arrestin in rod photoreceptors is signaled through a phospholipase C cascade and requires ATP. Cell Signal. 2010;22:447–456. doi: 10.1016/j.cellsig.2009.10.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Peet JA, Bragin A, Calvert PD, Nikonov SS, Mani S, et al. Quantification of the cytoplasmic spaces of living cells with EGFP reveals arrestin-EGFP to be in disequilibrium in dark adapted rod photoreceptors. J Cell Sci. 2004;117:3049–3059. doi: 10.1242/jcs.01167. [DOI] [PubMed] [Google Scholar]
  • 53.Slepak VZ, Hurley JB. Mechanism of light-induced translocation of arrestin and transducin in photoreceptors: interaction-restricted diffusion. IUBMB Life. 2008;60:2–9. doi: 10.1002/iub.7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Bayburt TH, Vishnivetskiy SA, McLean M, Morizumi T, Huang CC, et al. Rhodopsin monomer is sufficient for normal rhodopsin kinase (GRK1) phosphorylation and arrestin-1 binding. J Biol Chem. 2011;286:1420–1428. doi: 10.1074/jbc.M110.151043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Tsukamoto H, Sinha A, Dewitt M, Farrens DL. Monomeric Rhodopsin Is the Minimal Functional Unit Required for Arrestin Binding. J Mol Biol. 2010;399:501–511. doi: 10.1016/j.jmb.2010.04.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Nair KS, Hanson SM, Kennedy MJ, Hurley JB, Gurevich VV, et al. Direct binding of visual arrestin to microtubules determines the differential subcellular localization of its splice variants in rod photoreceptors. J Biol Chem. 2004;279:41240–41248. doi: 10.1074/jbc.M406768200. [DOI] [PubMed] [Google Scholar]
  • 57.Hanson SM, Francis DJ, Vishnivetskiy SA, Klug CS, Gurevich VV. Visual arrestin binding to microtubules involves a distinct conformational change. J Biol Chem. 2006;281:9765–9772. doi: 10.1074/jbc.M510738200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Song X, Raman D, Gurevich EV, Vishnivetskiy SA, Gurevich VV. Visual and both non-visual arrestins in their "inactive" conformation bind JNK3 and Mdm2 and relocalize them from the nucleus to the cytoplasm. J Biol Chem. 2006;281:21491–21499. doi: 10.1074/jbc.M603659200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Ahmed MR, Zhan X, Song X, Gurevich VV, Gurevich EV. Ubiquitin ligase parkin promotes Mdm2-arrestin interaction but inhibits arrestin ubiquitination. Biochemistry. 2011;50:3749–3763. doi: 10.1021/bi200175q. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Wu N, Hanson SM, Francis DJ, Vishnivetskiy SA, Thibonnier M, et al. Arrestin binding to calmodulin: a direct interaction between two ubiquitous signaling proteins. J Mol Biol. 2006;364:955–963. doi: 10.1016/j.jmb.2006.09.075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Huang SP, Brown BM, Craft CM. Visual Arrestin 1 acts as a modulator for N-ethylmaleimide-sensitive factor in the photoreceptor synapse. J Neurosci. 2010;30:9381–9391. doi: 10.1523/JNEUROSCI.1207-10.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Smith WC, Bolch SN, Dugger DR, Li J, Esquenazi I, et al. Interaction of arrestin with enolase1 in photoreceptors. Invest Ophthalmol Vis Sci. 2011;52:1832–1840. doi: 10.1167/iovs.10-5724. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Eckmiller MS. Microtubules in a rod-specific cytoskeleton associated with outer segment incisures. Vis Neurosci. 2000;17:711–722. doi: 10.1017/s0952523800175054. [DOI] [PubMed] [Google Scholar]
  • 64.Nir I, Ransom N. S-antigen in rods and cones of the primate retina: different labeling patterns are revealed with antibodies directed against specific domains in the molecule. J Histochem Cytochem. 1992;40:343–352. doi: 10.1177/40.3.1372630. [DOI] [PubMed] [Google Scholar]
  • 65.Nir I, Ransom N. Ultrastructural analysis of arrestin distribution in mouse photoreceptors during dark/light cycle. Exp Eye Res. 1993;57:307–318. doi: 10.1006/exer.1993.1129. [DOI] [PubMed] [Google Scholar]
  • 66.Hanson SM, Cleghorn WM, Francis DJ, Vishnivetskiy SA, Raman D, et al. Arrestin mobilizes signaling proteins to the cytoskeleton and reidrects their activity. J Mol Biol. 2007;368:375–387. doi: 10.1016/j.jmb.2007.02.053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Chen CK, Woodruff ML, Chen FS, Chen D, Fain GL. Background light produces a recoverin-dependent modulation of activated-rhodopsin lifetime in mouse rods. J Neurosci. 2010;30:1213–1220. doi: 10.1523/JNEUROSCI.4353-09.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Song X, Vishnivetskiy SA, Gross OP, Emelianoff K, Mendez A, et al. Enhanced Arrestin Facilitates Recovery and Protects Rods Lacking Rhodopsin Phosphorylation. Current Biology. 2009;19:700–705. doi: 10.1016/j.cub.2009.02.065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Lyubarsky AL, Lem J, Chen J, Falsini B, Iannaccone A, et al. Functionally rodless mice: transgenic models for the investigation of cone function in retinal disease and therapy. Vision Res. 2002;42:401–415. doi: 10.1016/s0042-6989(01)00214-0. [DOI] [PubMed] [Google Scholar]
  • 70.Pepperberg DR, Cornwall MC, Kahlert M, Hofmann KP, Jin J, et al. Light-dependent delay in the falling phase of the retinal rod photoresponse. Vis Neurosci. 1992;8:9–18. doi: 10.1017/s0952523800006441. [DOI] [PubMed] [Google Scholar]
  • 71.Birch DG, Hood DC, Nusinowitz S, Pepperberg DR. Abnormal activation and inactivation mechanisms of rod transduction in patients with autosomal dominant retinitis pigmentosa and the pro-23-his mutation. Invest Ophthalmol Vis Sci. 1995;36:1603–1614. [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES